Tag: MedinCell
MedinCell publishes its consolidated annual financial results – 06/14/2022 at 17:45
Income from ordinary activities: €8.3 million Operating expenses: €32.2 million, of which 73% devoted to Research & Development Consumption of cash related to the activity: 21.4 M€ Cash available as…
MedinCell: Teva Provides Additional Information for mdc-IRM Approval Application
By Alexandra Saintpierre Published on 05/03/2022 at 9:54 p.m. Photo credit © Reuters …
Teva, partner of MedinCell, provides additional information regarding the application for approval of mdc-IRM – 05/03/2022 at 21:00
Kåre Schultz, Chairman and Chief Executive Officer of Teva, spoke today during the presentation of the results for the first quarter of 2022. He provided information following the recent receipt…
Mithra Pharmaceuticals SA: CDMO announces collaboration with MedinCell for the development of injectables against malaria and transplant rejection
Liège, Belgium, April 26, 2022 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, announces today that it has signed a partnership agreement with MedinCell…
Mithra CDMO announces collaboration with MedinCell for the development of injectables against malaria and transplant rejection – 04/26/2022 at 07:30
Liège, Belgium, April 26, 2022 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, announces today that it has signed a partnership agreement with MedinCell…
MedinCell SA: Teva and MedinCell received full response letter for TV-46000/mdc-IRM
PARSIPPANY, NJ, TEL AVIV & PARIS – Teva Pharmaceuticals, American subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) today announce that the U.S. Food…
MedinCell SA: provides additional information regarding mdc-IRM’s application for approval
As announced*, Teva recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of TV-46000/mdc- MRI. Christophe Douat, Chairman…
Teva and MedinCell have received a complete response letter for TV-46000/mdc-IRM – 04/19/2022 at 23:15
PARSIPPANY, NJ, TEL AVIV & PARIS – Teva Pharmaceuticals, US subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) today announce that the U.S. Food…
MedinCell provides additional information regarding mdc-IRM’s application for approval – 04/19/2022 at 23:45
As announced, Teva recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of TV-46000/mdc-IRM . Christophe Douat, Chairman…
Medincell in the home stretch for treatment of schizophrenia
Subscribe for 1 € Unlimited access to all advice Over 800 securities listed in Paris and abroad scrutinized. To buy ? To sell ? What course objective? Our experts get…
MedinCell wants to revolutionize the way medication is taken
Teva factory, in Jerusalem (Israel), in 2017. THOMAS COEX / AFP It is perhaps a major turning point for the French MedinCell. The Israeli pharmaceutical company Teva unveiled, at the…